Assertio Therapeutics (ASRT) Tops Q1 EPS by 4c, provides guidance

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of $0.04, $0.04 better than the analyst estimate of $0.00. Revenue for the quarter came in at $31.9 million versus the consensus estimate of $28 million.

GUIDANCE:

Assertio Therapeutics sees FY2024 revenue of $110-125 million, versus the consensus of $117.3 million. And adjusted EBITDA of $20 million to $30 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI